A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Conditions:   Melanoma;   Breast Carcinoma;   Hepatocellular Carcinoma;   Urothelial Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Renal Cell Carcinoma;   Colorectal Carcinoma;   Non-small Cell Lung Carcinoma;   Gastric or Gastroesophageal Junction Adenocarcinoma;   Endometrial Carcinoma
Intervention:   Biological: XmAb20717
Sponsors:   Xencor, Inc.;   ICON plc
Not yet recruiting

https://ift.tt/2rp9WXy